Skip to content

Study · Animal study (in vivo) · rat · 2000

23 results

The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.

Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO

The Journal of endocrinology1 Jun 2000Cited by 16 (Europe PMC)

PMID10828840 (opens in a new tab)DOI10.1677/joe.0.1650569 (opens in a new tab)PepBankPUB-10828840
Source linkPubMedAsk about this study
Jump to 23 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study23

23 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, 12 weeks of GHRP‑6 increased body weight compared with vehicle.

    In plain wordsIn female rats, 12 weeks of GHRP‑6 raised body weight compared with vehicle.

    Peptide
    GHRP-6
    Outcome
    IncreaseBody weight
    Study

    ratn = 8

    young adult female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    All treatments increased body weight and total tibial and vertebral BMC measured by DXA in vivo compared with vehicle-treated controls.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, GHRP‑6 increased total tibial and vertebral bone mineral content measured by DXA compared with vehicle.

    In plain wordsIn female rats, GHRP‑6 increased bone mineral content compared with vehicle.

    Peptide
    GHRP-6
    Outcome
    IncreaseTotal tibial and vertebral BMC by DXA
    Study

    ratn = 8

    young adult female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    All treatments increased body weight and total tibial and vertebral BMC measured by DXA in vivo compared with vehicle-treated controls.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, total BMC corrected for body weight was unaffected by GHRP‑6.

    In plain wordsIn female rats, once body weight was taken into account, GHRP‑6 did not change bone mineral content.

    Peptide
    GHRP-6
    Outcome
    No significant changeTotal BMC corrected for body weight
    Study

    ratn = 8

    young adult female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    However, total BMC corrected for the increase in body weight (total BMC:body weight ratio) was unaffected.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, tibial area BMD was increased after the treatments including GHRP‑6.

    In plain wordsIn female rats, tibial bone density per area was higher after GHRP‑6 treatment.

    Peptide
    GHRP-6
    Outcome
    IncreaseTibial area bone mineral density
    Study

    ratn = 8

    young adult female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    Tibial area bone mineral density (BMD, BMC/area) was increased, but total and vertebral area BMDs were unchanged.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, total and vertebral area BMDs were unchanged.

    In plain wordsIn female rats, total and vertebral bone density per area did not change.

    Peptide
    GHRP-6
    Outcome
    No significant changeTotal and vertebral area BMD
    Study

    ratn = 8

    young adult female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    but total and vertebral area BMDs were unchanged.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, the increase in cortical BMC was due to an increased cross-sectional bone area.

    In plain wordsIn female rats, the rise in outer bone mineral content came from larger bone area.

    Peptide
    GHRP-6
    Outcome
    IncreaseCortical BMC and cross-sectional bone area by pQCT
    Study

    ratn = 8

    young adult female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    The pQCT measurements in vitro revealed that the increase in the cortical BMC was due to an increased cross-sectional bone area, whereas the cortical volumetric BMD was unchanged.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, cortical volumetric BMD was unchanged.

    In plain wordsIn female rats, the density of the outer bone layer did not change.

    Peptide
    GHRP-6
    Outcome
    No significant changeCortical volumetric BMD by pQCT
    Study

    ratn = 8

    young adult female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    whereas the cortical volumetric BMD was unchanged.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, femur and vertebra L6 volumes were increased.

    In plain wordsIn female rats, thigh bone and spine bone volumes were larger.

    Peptide
    GHRP-6
    Outcome
    IncreaseFemur and vertebra L6 volumes
    Study

    ratn = 8

    young adult female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    Femur and vertebra L6 volumes were increased but no effect was seen on the volumetric BMDs as measured by Archimedes' principle.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, volumetric BMDs measured by Archimedes' principle were not changed.

    In plain wordsIn female rats, bone density measured by volume did not change.

    Peptide
    GHRP-6
    Outcome
    No significant changeVolumetric BMD by Archimedes' principle
    Study

    ratn = 8

    young adult female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    but no effect was seen on the volumetric BMDs as measured by Archimedes' principle.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, ash weight was increased by the treatments including GHRP‑6.

    In plain wordsIn female rats, GHRP‑6 raised bone ash weight.

    Peptide
    GHRP-6
    Outcome
    IncreaseAsh weight
    Study

    ratn = 8

    young adult female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    Ash weight was increased by all treatments, but the mineral concentration was unchanged.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, bone mineral concentration was unchanged.

    In plain wordsIn female rats, the mineral concentration of bone did not change.

    Peptide
    GHRP-6
    Outcome
    No significant changeMineral concentration
    Study

    ratn = 8

    young adult female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    but the mineral concentration was unchanged.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, 12 weeks of ipamorelin increased body weight compared with vehicle-treated controls.

    In plain wordsIn rats, 12 weeks of ipamorelin increased body weight compared with vehicle.

    Peptide
    Ipamorelin
    Outcome
    IncreaseBody weight
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    All treatments increased body weight
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, 12 weeks of ipamorelin increased total tibial bone mineral content measured by DXA compared with vehicle.

    In plain wordsIn rats, 12 weeks of ipamorelin increased the mineral content of the shin bone compared with vehicle.

    Peptide
    Ipamorelin
    Outcome
    IncreaseTotal tibial bone mineral content by DXA
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    All treatments increased body weight and total tibial and vertebral BMC measured by DXA in vivo compared with vehicle-treated controls.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, 12 weeks of ipamorelin increased total vertebral bone mineral content measured by DXA compared with vehicle.

    In plain wordsIn rats, 12 weeks of ipamorelin increased the mineral content of spine bones compared with vehicle.

    Peptide
    Ipamorelin
    Outcome
    IncreaseTotal vertebral bone mineral content by DXA
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    All treatments increased body weight and total tibial and vertebral BMC measured by DXA in vivo compared with vehicle-treated controls.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, total bone mineral content corrected for body weight was unaffected by ipamorelin.

    In plain wordsIn rats, after correcting for body weight, ipamorelin did not change total bone mineral content.

    Peptide
    Ipamorelin
    Outcome
    No significant changeTotal BMC corrected for body weight
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    However, total BMC corrected for the increase in body weight (total BMC:body weight ratio) was unaffected.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, tibial area bone mineral density was increased after 12 weeks of ipamorelin.

    In plain wordsIn rats, 12 weeks of ipamorelin increased the density of the shin bone.

    Peptide
    Ipamorelin
    Outcome
    IncreaseTibial area bone mineral density
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    Tibial area bone mineral density (BMD, BMC/area) was increased
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  17. 17AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, total and vertebral area bone mineral densities were unchanged after ipamorelin.

    In plain wordsIn rats, ipamorelin did not change the density of the whole skeleton or the spine bones.

    Peptide
    Ipamorelin
    Outcome
    No significant changeTotal and vertebral area bone mineral density
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    but total and vertebral area BMDs were unchanged.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  18. 18AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, ipamorelin increased cortical bone mineral content, which was due to an increased cross-sectional bone area.

    In plain wordsIn rats, ipamorelin increased the mineral content of outer bone because the bones grew larger in cross-section.

    Peptide
    Ipamorelin
    Outcome
    IncreaseCortical bone mineral content and cross-sectional bone area (pQCT)
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    The pQCT measurements in vitro revealed that the increase in the cortical BMC was due to an increased cross-sectional bone area
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  19. 19AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, cortical volumetric bone mineral density was unchanged after ipamorelin.

    In plain wordsIn rats, ipamorelin did not change the volumetric density of outer bone.

    Peptide
    Ipamorelin
    Outcome
    No significant changeCortical volumetric bone mineral density (pQCT)
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    whereas the cortical volumetric BMD was unchanged.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  20. 20AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, femur and vertebra L6 volumes were increased after ipamorelin.

    In plain wordsIn rats, ipamorelin increased the volume of the thigh bone and a spine bone.

    Peptide
    Ipamorelin
    Outcome
    IncreaseFemur and vertebra L6 volumes
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    Femur and vertebra L6 volumes were increased
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  21. 21AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, ipamorelin had no effect on femur and vertebra L6 volumetric bone mineral densities measured by Archimedes' principle.

    In plain wordsIn rats, ipamorelin did not change the volumetric density of the thigh bone or a spine bone.

    Peptide
    Ipamorelin
    Outcome
    No significant changeVolumetric bone mineral density by Archimedes' principle
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    but no effect was seen on the volumetric BMDs as measured by Archimedes' principle.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  22. 22AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, ash weight of bone was increased after ipamorelin.

    In plain wordsIn rats, ipamorelin increased the ash weight of bone, a measure of its mineral amount.

    Peptide
    Ipamorelin
    Outcome
    IncreaseAsh weight
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    Ash weight was increased by all treatments
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.
  23. 23AnimalAnimal study (in vivo)Efficacy outcome

    In adult female rats, the mineral concentration of bone was unchanged after ipamorelin.

    In plain wordsIn rats, ipamorelin did not change the mineral concentration of bone.

    Peptide
    Ipamorelin
    Outcome
    No significant changeBone mineral concentration
    Study

    ratn = 7

    Thirteen-week-old female Sprague-Dawley rats
    Comparator
    Vehicle
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    0.5 mg/kg per day · subcutaneous (osmotic minipump) · 12 weeksAs given in this study (rat).

    Source sentences

    Summary
    but the mineral concentration was unchanged.
    1 context sentence
    Summary · context
    Thirteen-week-old female Sprague-Dawley rats were given IPA (0.5 mg/kg per day; n=7), GHRP-6 (0.5 mg/kg per day; n=8), GH (3.5 mg/kg per day; n=7), or vehicle administered continuously s.c. via osmotic minipumps for 12 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 26 to 43Current

    28 Oct 2026, 02:02 UTC

    The same notice was added 18 times, first on 14 Oct 2026, 05:01 UTC. The status did not change between them.

    Study results updated

  2. Version 25

    14 Oct 2026, 01:46 UTC

    Study data updated · source update from Europe PMC

  3. Versions 3 to 24

    13 Oct 2026, 21:46 UTC

    The same notice was added 22 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  4. Version 2

    9 Oct 2026, 03:13 UTC

    Study data updated · source update from Europe PMC

  5. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.